News

Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today issued a statement regarding the recently identified SARS-CoV-2 variant, termed Omicron (B.1.1.529)1. The...

read more

Clinical data published of a novel serum biomarker quintet that improves disease prognosis in men with confirmed prostate cancer

Zurich-Schlieren, Switzerland, November 18, 2021. Proteomedix, the Swiss diagnostics company committed to advance prostate cancer care, today announced the publication of clinical data that reveal added prognostic value of a blood biomarker signature predicting biochemical recurrence and adverse pathology in prostate cancer patients. Radical prostatectomy provides excellent cancer control of clinically...

read more

Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a planned futility analysis of ensovibep...

read more